Flexion Therapeutics FLXN 深 滬
已收盤 08-08 16:00:00 美东时间
25.2299
+0.030
+0.12%
華盛通- 最 高25.2299
- 今 開25.2283
- 成交量 787股
- 最 低 25.20
- 昨 收 25.1999
- 總市值 3229.43万
- 52周最高 25.2694
- 市盈率 靜 --
- 換手率 0.06%
- 52周最低 4.30
- 委 比 0.00%
- 總股本 128.00万
- 歷史最高 32.25
- 量 比 0.46
- 振 幅 0.12%
- 歷史最低 4.30
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
Lexicon Pharmaceuticals reported second quarter 2025 financial results, highlighting increased revenues due to licensing agreements, particularly with Novo Nordisk for LX9851. Key milestones include partnership discussions for pilavapadin progressing, completion of IND-enabling studies for LX9851 expected by 2025, and enrollment on track for the SONATA Phase 3 study in HCM. Additionally, Lexicon remains focused on advancing sotagliflozin in heart...
08-06 11:30
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
Lexicon Pharmaceuticals announced they will release their second quarter 2025 financial results on August 6, 2025, followed by a conference call and webcast at 8:30 a.m. ET. The webcast and archived version will be available on their website.
07-23 12:00
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
Lexicon announced data from a study on diabetic peripheral neuropathic pain (DPNP) patients despite standard treatment, to be presented at the ASPN 2025 meeting. DPNP, a debilitating complication of diabetes affecting millions, often impacts daily life. Lexicon’s investigational drug, pilavapadin, a novel non-opioid treatment targeting AAK1, showed promising results in reducing DNP pain in Phase 2a trials. The company aims to raise awareness of D...
07-18 12:00
Horizon Expands ETF Lineup With 2 Funds For Smarter Bond Income And Volatility Defense
Horizon introduces 2 new ETFs for financial advisors - BNDY and FLXN - to help manage risk and enhance returns in complex markets.
07-08 04:05
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Lexicon Pharmaceuticals announced that a post-hoc analysis of data from clinical trials showed that adding sotagliflozin to optimized insulin therapy significantly reduced hypoglycemic events, particularly in individuals with type 1 diabetes (T1D) experiencing blood glucose levels ≤55 mg/dL. The study, presented at the American Diabetes Association's 85th Scientific Sessions, evaluated the impact of kidney function on hypoglycemia risk using esti...
06-23 12:00
Pacira生物科学公司完成对屈曲治疗公司的收购并加强在非阿片类疼痛管理方面的领先地位
-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Comb...
2021-11-19 21:46
Alentis Therapeutics宣布任命Luca Santarelli为董事会成员，Rafaèle Tordjman为董事长
瑞士巴塞尔--(BUSINESS WIRE)--(美国商业资讯)--开发纤维化疾病突破性治疗药物的瑞士生物技术公司Alentis Therapeutics今天宣...
2021-11-15 17:20
股东通知：Brodsky&Smith公司宣布对Flexion治疗公司(纳斯达克-FLXN)进行调查
BALA CYNWYD, PA / ACCESSWIRE / October 13, 2021 / Law office of Brodsky & S...
2021-10-13 19:18
药闻头条丨Moderna急了！敦促FDA授权加强针，赛生新抗生素拟上市
欧康维视自研干眼症药首度获批临床；歌礼慢性乙肝药将公布二期临床数据；阿斯利康在华设立全球研发中心>>
2021-10-13 13:37
